Medical/Pharmaceuticals
AIM Vaccine Forecasts Surge in Stock Performance: Innovations Reinforce Leadership in Vaccine Sector
HONG KONG, Aug. 28, 2025 /PRNewswire/ -- AIM Vaccine (06660.HK), a leading domestic vaccine company, announced today the release of its 2025 interim report, showcasing robust revenue growth. With major products entering the market phase, R&D costs are decreasing, and operational expenditures are ...
2025-08-28 07:45
3927
XtalPi Holdings Announces 2025 Interim Results
SHENZHEN, China, Aug. 27, 2025 /PRNewswire/ -- Key Highlights from the Financial Report: * Revenue surged 404% year over year to RMB 517 million in the first half of 2025. * Adjusted net profit reached RMB 141 million, marking the company's first-ever half-year profitability. * XtalPi wa...
2025-08-27 22:26
6322
Neusoft Medical Systems Launches China's First Photon-Counting CT with NMPA Approval
SHENYANG, China, Aug. 27, 2025 /PRNewswire/ -- Neusoft Medical Systems today announced that its NeuViz P10 photon-counting CT has received market approval fromChina's National Medical Products Administration (NMPA). This marks the first photon‑counting CT approved inChina, and the world's first w...
2025-08-27 21:03
2897
Fosun International: Total Revenue for the First Half of 2025 Reaches RMB87.28 Billion, Industrial Operation Profit Amounts to RMB3.15 Billion
HONG KONG, Aug. 27, 2025 /PRNewswire/ -- On 27 August, Fosun International Limited (HKEX stock code: 00656) announced its interim results for the six months ended30 June 2025. In the first half of 2025, Fosun actively captured macroeconomic trends, maintained a clear strategic focus, and leverag...
2025-08-27 20:40
4682
Digital twin technology with AI to boost efficiency and reliability in pharmaceutical manufacturing
* Cambridge Advanced Research and Education in Singapore (CARES), the University of Cambridge's first overseas research centre, together with the A*STAR Institute for Infocomm Research (A*STAR I2R) has developed a digital twin platform that uses artificial intelligence (AI) and real-time plant ...
2025-08-27 13:00
2188
Crescom to Showcase Musculoskeletal AI Innovations at 26th Asian Musculoskeletal Society Annual Meeting
Company to present MediAI solution suite and strengthen partnerships for expansion across Southeast andEast Asia SEOUL, South Korea, Aug. 27, 2025 /PRNewswire/ -- Crescom, a leader in AI-powered musculoskeletal (MSK) image analysis software, announced its participation in the 26th Asian Musculos...
2025-08-27 09:00
2161
Cerecin Joins NIHR HealthTech Research Centre in Brain Health as an Industry Partner
DENVER, Aug. 27, 2025 /PRNewswire/ -- Cerecin, a global biotech company focused on neurometabolism, is proud to announce its partnership with the NIHR HealthTech Research Centre (HRC) in Brain Health, joining a distinguished group of industry leaders including GE Healthcare, Novo Nordisk, Roche D...
2025-08-27 00:04
2669
ZEISS showcases comprehensive workflow for full spectrum of retina care at EURETINA
At EURETINA 2025, ZEISS Medical Technology combines its diagnostic, surgical and digital technologies to support healthcare professionals in advancing retinal care: * IMPROVE PATHOLOGY DETECTION: Now CE mark approved, CIRRUS® PathFinderTM AI decision support tool streamlines OCT data review; I...
2025-08-26 20:00
1935
Abbott receives regulatory approval for the first denosumab biosimilar in Thailand, expanding access to bone disease treatment
* Abbott's denosumab biosimilar is the first approved in Thailand, making advanced therapy for osteoporosis and cancer-related bone loss more affordable for millions of Thais * This approval builds on Abbott's biosimilar portfolio in Asia Pacific, following recent launches inMalaysia and Indi...
2025-08-26 14:29
3031
Basecare Medical (02170.HK) Gems Culture Medium Receives First Approval from NMPA, Advancing the Localization of Assisted Reproductive Fluids
SUZHOU, China, Aug. 26, 2025 /PRNewswire/ -- Recently, Suzhou Basecare Medical Co., Ltd. achieved a major breakthrough—its globally leading Gems culture medium (embryo handling solution VitBase) has officially received registration approval from the National Medical Products Administration (NMPA)...
2025-08-26 11:47
4111
Fullerton Health Announces Strategic Investment by Mitsubishi Corporation
SINGAPORE, Aug. 26, 2025 /PRNewswire/ -- Fullerton Health Pte. Ltd. ("Fullerton Health" or the "Company"), a leading healthcare solutions provider operating in nine markets acrossAsia-Pacific, today announced that Mitsubishi Corporation has acquired a strategic minority stake in the Company. This...
2025-08-26 10:00
2673
Infinitus Named in Liaowang Institution's "Leading Transparent Factory Case Studies"
GUANGZHOU, China, Aug. 26, 2025 /PRNewswire/ -- Amid the digital economy and shifting consumer expectations, "trust" has become a core driver of sustainable business growth. The "Transparent Factory • Building the Future with Trust — 2025 Trust Productivity High-End Dialogue" was held in Jiangmen...
2025-08-26 02:55
5062
Neopharma Technologies and Orient Gene Partner to Digitize Healgen® Drug Test Portfolio Globally with NEOVAULT®
Partnership delivers tamper-evident, high-integrity testing data aligned with U.S. Drug Policy Priorities WASHINGTON, Aug. 26, 2025 /PRNewswire/ -- Neopharma Technologies Limited ("Neopharma") today announced it hasentered into a global software licensing and collaboration agreement with Zhejian...
2025-08-26 02:10
2624
Henlius Keeps Steady Growth in H1 2025: Overseas Product Profits Soar 200%+, Innovation Fuels Global Reach
SHANGHAI, Aug. 25, 2025 /PRNewswire/ -- Henlius (2696.HK) announced its 2025 interim results. In the first half of 2025, Henlius' revenue reached about RMB2.8195 billion, representing an increase of 2.7% YoY. The gross profit of RMB2.1992 billion, up by 10.5% YoY, with a net profit reached RMB390....
2025-08-25 21:18
4943
Everest Medicines Announces Participation in September Investor Conferences
SHANGHAI, Aug. 25, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced thatIan Woo, President and Chief Fin...
2025-08-25 20:57
2445
Acceleration in Clinical Development! Leads Biolabs' LBL-034 Dosed First Patient in Phase Ⅱ Trial
NANJING, China, Aug. 25, 2025 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the first patient has been successfully dosed in the Phase Ⅱ trial of LBL-034 (GPRC5D/CD3 BsAb) following strong Phase Ⅰ data.This milestone endows...
2025-08-25 18:27
3926
Pulnovo Medical Names Dr. Francis Duhay as Global Chief Medical Officer
SHANGHAI, Aug. 25, 2025 /PRNewswire/ -- Pulnovo Medical, a global leader in mechanism-driven therapies for Pulmonary Hypertension (PH) and Heart Failure (HF), today announced the appointment ofFrancis Duhay, MD, MBA, FACS as Global Chief Medical Officer. Dr. Duhay, a board-certified General and ...
2025-08-25 16:42
3609
Lundbeck to present new data on bexicaserin at upcoming congress, highlighting long-term impact on seizure frequency in patients with rare epilepsy
* The full results of the open label extension (OLE) of the Phase 1b/2a PACIFIC trial investigating bexicaserin for the treatment of patients with Developmental and Epileptic Encephalopathies (DEEs), will be presented for the first time at the International Epilepsy Annual Congress1 * DEEs ar...
2025-08-25 15:43
1848
Cambrex Expands Peptide Manufacturing Capabilities in Waltham, Massachusetts
EAST RUTHERFORD, N.J., Aug. 25, 2025 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced that Snapdragon Chemistry, a Cambrex company, has expanded its active pharmaceutical ingredient (API) facility inWaltham, Massachusetts to fur...
2025-08-25 12:01
2950
Antengene Announces 2025 Interim Financial Results Highlighting Encouraging Data from Mid/Late-Stage Clinical Programs and Its Innovative TCE Technology Platform
* The Phase I/II CLINCH study of ATG-022 (CLDN18.2 antibody-drug conjugate) demonstrated promising results, showing robust clinical efficacy and a favorable safety profile in patients with gastric/gastroesophageal junction adenocarcinoma across high, low, and ultra-low CLDN18.2 expression level...
2025-08-22 18:14
3400
Week's Top Stories
Most Reposted
Agoda Releases AI Developer Report 2026: Agentic AI Adoption Outpaces Enterprise Readiness Across Southeast Asia and India
[Picked up by 294 media titles]
2026-09-24 10:30
HLB's Flagship CIO Fund Launched with Strategic Alliance with Lombard Odier
[Picked up by 278 media titles]
2026-09-28 23:04
Responsible Fintech Institute Appoints Four Executive Fellows and Elevates Distinguished Professor Patrick H. M. Loh to Co-Founder
[Picked up by 278 media titles]
2026-09-29 09:00
Malaysia Calls for Shift from Halal-Certified to Halal-Competitive as ASEAN Targets USD5 Trillion Global Halal Economy
[Picked up by 277 media titles]
2026-09-25 14:45
Nuix Recognised as a RiskTech100® 2027 Disruptor by Chartis Research
[Picked up by 274 media titles]
2026-09-25 08:30Most Read
Brightray Signs Prefabricated Module Sales Framework Agreement for Planned 40MW AI Data Center Project in Macao
2026-09-25 20:30
13957
Envision Energy Secures TÜV SÜD Certificate for Wind Farm Control System, Strengthening Long-Term Resilience for Future Energy Systems
2026-09-25 20:11
12660
ULTRALOQ Launches Next-Generation Smart Lock Collection: Refining Home Entry with Natural, Intelligent and Trusted Access Solutions
2026-09-26 02:46
11746
